Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToMP-AD: Senolytic Therapy in Alzheimer's Disease
NCT04685590Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of dasatinib, quercetin in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Washington University School of Medicine. Started Dec 2021; status: active, not recruiting.
02
Drugs
dasatinibquercetin
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04685590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685590.